Abstract 299P
Background
Neoadjuvant therapy (NAT) remains the standard of care for most early-stage breast cancer (BC) patients, especially in HER2+ and triple-negative (TNBC) subtypes. Patients who do not achieve pathological complete response (pCR) present an increased risk of disease recurrence. Here, we applied single cell RNA sequencing (SCS) to investigate tumor and immune landscape for the identification of predictive biomarkers of response to NAT.
Methods
Twenty-one BC patients treated with NAT were included in the study. Pre-treatment biopsies, matched residual disease and adjacent normal tissue samples were prospectively collected for all patients. After tissue dissociation, single cell RNA profiles were investigated using the Chromium Next GEM Single Cell 5' kit (10X Genomics). After removing batch effect using Seurat integration, cell clusters were annotated based on the expression of specific marker genes. Epithelial luminal cells (KRT18+/KRT19+) were classified as malignant or non-malignant using copy number profiles computed by inferCNV. Wilcoxon rank sum test was used to compare cell proportions between pCR and non-pCR groups.
Results
pCR rates were 61.5% (8/13), 100% (4/4) and 25% (1/4) in TNBC, HER2+ and Luminal B patients respectively. A total of 21 TNBC, 6 HER2+ and 6 Luminal B samples were profiled with SCS. Malignant luminal epithelial cells were classified in luminal progenitor (LP) (KIT+/SLPI+/KRT5low), luminal mature (LM) (KIT-/SLPI-/KRT5-) and luminal cycling cells (LC) (MKI67+/TOP2A+). Patients achieving pCR had a higher fraction of LC cells at baseline, considering all BC subtypes (p<0.05). Enrichment of LP cells at baseline was observed in TNBC patients achieving pCR (p<0.05). T cells reclustering further identified four CD4+ subtypes. Of note, lower proportions of FOXP3+ regulatory T cells and RORC+/CCR6+ Th17 cells at baseline were associated with a better response to NAT both in TNBC and HER2+ patients (p<0.05).
Conclusions
Our study showed substantial heterogeneity at the single cell level with specific cell types being associated with response to neoadjuvant chemotherapy, towards an improved BC care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B).
Funding
Fond de la Recherche Scientifique (FNRS), Télévie, Association Jules Bordet, Breast Cancer Research Foundation (BCRF), Fondation contre le Cancer, Fondation de l’Université Libre de Bruxelles.
Disclosure
C. Sotiriou: Financial Interests, Institutional, Advisory Board: Astellas, Vertex, Seattle Genetics, Amgen, INC, Merck & Co; Financial Interests, Personal, Advisory Board: Cepheid, Puma; Financial Interests, Personal, Invited Speaker: Eisai, Prime oncology, Teva; Financial Interests, Institutional, Other, Travel: Roche; Financial Interests, Institutional, Other, Internal speaker: Genentech; Financial Interests, Personal, Other, Regional speaker: Pfizer; Financial Interests, Institutional, Invited Speaker: Exact Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
304P - Generalizability of 313-SNP PRS for breast cancer risk in non-European ancestries
Presenter: Helen Shang
Session: Poster session 02
305P - Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
Presenter: Sora Kang
Session: Poster session 02
307P - Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline
Presenter: Xixuan Zhu
Session: Poster session 02
308P - Regression-based deep-learning predicts breast cancer recurrence risk score from pathology slides
Presenter: Omar El Nahhas
Session: Poster session 02
310P - Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
Presenter: Mitchell Elliott
Session: Poster session 02
311P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on the genetic counselling experience
Presenter: Ranjit Kaur
Session: Poster session 02
312P - Prediction model of breast cancer patient’s neoadjuvant treatment outcome using breast cancer organoids cultured from core needle biopsies
Presenter: Dong Woo Lee
Session: Poster session 02
313P - Intrinsic subtypes in a cohort of early breast cancer patients
Presenter: Theresa Bracht
Session: Poster session 02